Description: Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. It is developing KidneyIntelX, an AI-enabled, clinical-laboratory based solution that supports physician decision making by improving identification, prediction, and risk stratification of patients with kidney disease. The company is based in Cardiff, the United Kingdom. Renalytix AI plc (AIM:RENX) operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.
Home Page: renalytix.com
RENX Technical Analysis
1460 Broadway
New York,
NY
10036
United States
Phone:
646 397 3970
Officers
| Name | Title |
|---|---|
| Mr. James R. McCullough M.B.A. | CEO & Exec. Director |
| Mr. Fergus Fleming | CTO & Exec. Director |
| Mr. Thomas H. McLain CPA, M.B.A | Pres |
| Mr. Oliver James Sterling III | Chief Financial Officer |
| Ms. Andria Parks-Herrera | VP of Marketing |
| Ms. Jean M. Casner | Sr. VP & Chief HR Officer |
| Mr. Baljit Singh | Head of Clinical Operations |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer |
| Mr. Salim Hamir F.C.A. | Company Sec. |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9006 |
| Price-to-Sales TTM: | 18.4143 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 102 |